Drug Trial Radar · NCT00294515
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Last checked: Nov 20, 2026Latest source record: Mar 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
326
Actual
Start
Mar 31, 2006
Primary completion
Aug 31, 2008
Study completion Aug 31, 2009
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 22, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will determine the relative efficacy and safety of up to 100 days Valcyte prophylaxis relative to up to 200 days Valcyte prophylaxis when given for the prevention of CMV disease in high-risk (D+/R-) kidney allograft recipients. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Conditions
- Cytomegalovirus Infections
Interventions
ValganciclovirDrug
900 mg orally daily for up to 100 days
ValganciclovirDrug
900 mg orally daily for up to 200 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplantTime frame: 12 months post-transplant
Locations
80 sites in 13 countries. Site status is shown where the registry gives one.
Uni of Alabama At Birmingham
Birmingham, Alabama
National Institute of Transplantation
Los Angeles, California
UCLA Medical Center
Los Angeles, California
Ucsd Medical Center; Kidney Transplantation
San Diego, California
California Pacific Medical Center
San Francisco, California
Uni of California San Francisco; Transplant Services
San Francisco, California
Lifelink Healthcare Inst.
Tampa, Florida
Rush-Presbyterian St. Luke'S Medical Center; Rush Uni Renal Transplant Program
Chicago, Illinois
Indiana Uni Medical Center; Surgery & Microbiology/Immunology
Indianapolis, Indiana
New England Medical Center; Division of Transplant Surgery
Boston, Massachusetts
Uni of Michigan Medical Center
Ann Arbor, Michigan
Uni of Minnesota Medical Center; Dept of Surgery
Minneapolis, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
St. Barnabas Medical Center
Livingston, New Jersey
Robert Wood Johnson Uni Hospital; Anesthesia
New Brunswick, New Jersey
Wake Forest Uni School of Medicine; Section on Infectious Diseases
Winston-Salem, North Carolina
Oregon Health Sciences Uni ; Division of Nephrology
Portland, Oregon
Hahnemann Uni Hospital; Division of Transplant/Dept. of Surgery
Philadelphia, Pennsylvania
Uni of Pennslyvania Medical Center
Philadelphia, Pennsylvania
Vanderbilt Uni ; Divison of Nephrology
Nashville, Tennessee
Texas Transplant Inst.
San Antonio, Texas
Uni of Texas Health Science Center At San Antonio; Organ Transplant Program
San Antonio, Texas
Uni of Washington Medical Center; Division of Allergy & Infectious Diseases
Seattle, Washington
Royal Prince Alfred Hospital; Renal Transplant Unit
Camperdown, New South Wales, Australia
Monash Medical Centre; Renal Transplant Unit
Clayton, Victoria, Australia
Royal Melbourne Hospital; Nephrology
Parkville, Victoria, Australia
Clin Univ de Bxl Hôpital Erasme
Brussels, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clinicas - UNICAMP
Campinas, São Paulo, Brazil
Hospital Israelita Albert Einstein; Intensive Care Unit
São Paulo, São Paulo, Brazil
Faculdade de Medicina de Ribeirao Preto Usp; Campus Uni Rio
São Paulo, São Paulo, Brazil
Uni of Alberta Hospital
Edmonton, Alberta, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Mcgill University - Royal Victoria Hospital; Oncology
Montreal, Quebec, Canada
Hopital Pellegrin; Departement Nephrologie
Bordeaux, France
Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie
Grenoble, France
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.